ChemicalBook > CAS DataBase List > Pivekimab
Pivekimab
- Product Name
- Pivekimab
- CAS No.
- 2234335-84-1
- Chemical Name
- Pivekimab
- Synonyms
- Pivekimab;Research Grade Pivekimab;Research Grade Pivekimab(DHD72502)
- CBNumber
- CB410617090
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Pivekimab Property
- form
- Liquid
- color
- Colorless to light yellow
More
Less
Pivekimab Chemical Properties,Usage,Production
Uses
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN)[1][2].
References
[1] Patrick ZM, et, al. Methods of treatment using anti-CD123 immunoconjugates. WO2020092533.
[2] Poussard, et al. Spatial Response to Pivekimab Sunirine (IMGN632) In Vivo in a BPDCN Model. Blood 142 (2023): 2791.
Pivekimab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Pivekimab Suppliers
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58
- Tel
- 027-87008169 17762441161
- info@atagenix.com
- Country
- China
- ProdList
- 10001
- Advantage
- 58
- Tel
- 33175446423
- support@antibodysystem.com
- Country
- China
- ProdList
- 6739
- Advantage
- 58
- Tel
- 9785721070
- info@cellsciences.com
- Country
- China
- ProdList
- 6308
- Advantage
- 58
2234335-84-1, PivekimabRelated Search:
galiximab
Zolbetuximab
Gemtuzumab
Carlumab
Onvatilimab
Foralumab
Andecaliximab
Rovalpituzumab
Stamulumab
EFALIZUMABUM